Crescita Therapeutics Inc (CTX) Fair Value & Analysis
Healthcare · CA · Market cap C$14.7M
Fair value as of: Jun 24, 2026
From 12 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from C$1.25 to C$0.9600 (−23.2%) since Jun 23, 2026. Share price +3.9% over the past month.
Price vs Fair Value (12 months)
12‑month range C$0.4150 – C$0.7900 · fair‑value band C$0.8000 – C$1.11 · the C$0.7900 price screens below the C$0.9600 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Crescita Therapeutics Inc (CTX) currently trades at C$0.7900, while our model-based Fair Value estimate is C$0.9600 — implying the stock looks roughly 21.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Crescita Therapeutics Inc generated revenue of C$23.2M at a net margin of -1.4%. Revenue grew 59.4% year over year. It earns a return on equity of -2.2%. The balance sheet holds a net cash position of C$8.2M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary drug delivery platforms, which include Multiplexed Molecular Penetration Enhancers and DuraPee that supports the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures. Its non-prescription portfolio offers dermocosmetic products, such as face creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud and Aquafolia brands; and m…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Crescita Therapeutics Inc reported revenue of C$21.1M in FY2025 versus C$16.8M in FY2021, a compound +5.9%/yr. Reported net income was −C$92.0K in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.01 | ¥26.59 | -43% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Crescita Therapeutics Inc (CTX) undervalued?
What is the fair value of CTX?
What is the quality score of CTX?
What is the revenue of Crescita Therapeutics Inc (CTX)?
What is the net profit margin of CTX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.